Neurimmune welcomes the news that Biogen completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab as a treatment for Alzheimer’s disease. If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease and the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes.
Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich. In 2007 Neurimmune and Biogen entered into a collaborative development and license agreement for aducanumab's development and commercialization. Aducanumab was among the first human antibodies Neurimmune developed through its Reverse Translational Medicine platform.
"Today's news marks an important milestone in the development of aducanumab and significant progress in advancing a disease-modifying treatment for patients with Alzheimer's disease," said Roger Nitsch, CEO of Neurimmune. "We are proud to collaborate with Biogen on aducanumab and would like to thank them for their unwavering commitment and scientific excellence which has allowed us to advance the program in an outstanding way."
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Aducanumab is an investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease. Neurimmune has used its Reverse Translational Medicine technology to also discover cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving the vectorized expression of human antibody genes.
Contact for Media
Martin Meier-Pfister
+41 43 244 8140
media@neurimmune.com
